RNA Interference Pioneer Dr. Phillip Zamore Joins TransCode Therapeutics' Scientific Advisory Board

TransCode Therapeutics has appointed Dr. Phillip D. Zamore, a leading researcher in RNA interference (RNAi), to its Scientific Advisory Board. This strategic addition brings significant expertise to the clinical-stage oncology company's research and development efforts in RNA-targeted cancer therapies.

Dr. Zamore, currently serving as Chair of the RNA Therapeutics Institute at UMass Chan Medical School, is recognized for his foundational contributions to RNA biology and gene silencing mechanisms. His distinguished scientific career includes election to the National Academy of Sciences, underscoring his substantial impact on molecular research.

The appointment signals TransCode's commitment to advancing innovative cancer treatment strategies. The company's lead therapeutic candidate, TTX-MC138, focuses on treating metastatic tumors that overexpress microRNA-10b, a unique biomarker associated with metastasis. By leveraging Dr. Zamore's expertise, TransCode aims to enhance its proprietary TTX nanoparticle platform and develop more effective RNA therapeutic approaches.

With Dr. Zamore's extensive background in RNAi research and as a co-founder of Alnylam Pharmaceuticals, his involvement could potentially accelerate TransCode's ability to overcome current challenges in RNA delivery and unlock novel genetic targets for cancer treatment. His scientific insights may prove crucial in developing first-in-class RNA therapeutic candidates that could significantly impact oncology treatment strategies.

TransCode's leadership has expressed enthusiasm about Dr. Zamore's appointment, viewing it as a strategic enhancement to their scientific capabilities in developing targeted cancer therapies. The addition of such a prominent researcher demonstrates the company's dedication to pushing the boundaries of RNA-based medical interventions.